Biosonics, Inc., Names Peter Tobia as Financial Consultant.

FORT WASHINGTON, Pa.--(BW HealthWire)--Aug. 4, 1999--

Biosonics, Inc. (OTC BB:BISN), the Fort Washington-based electrotherapeutic solutions company, announces Peter G. Tobia as its full-time financial consultant to coordinate shareholder, investment and venture capital assignments.

Tobia, who has over 25 years entrepreneurial experience as a venture capital and financial planning executive, will assume many of Biosonics' responsibilities formerly held by the late Jack Paller, who was the company's President and CEO.

"Peter Tobia is an important addition to the Biosonics administrative and product development team that will help direct the expansion of the company," said Vice President Sandra Pileggi. "His experience and knowledge in public company finances and stockholder relations will be an invaluable resource for Biosonics."

Tobia was a principal and co-founder of eight public companies. He also served as President of a medical electronic subsidiary of a public company. He is a graduate of Rutgers University and a licensed professional engineer.

"Our initial focus will be to aggressively market, including the use of the Internet, existing FDA approved devices that Biosonics has developed," said Tobia. "We are actively seeking joint venture and marketing relationships with existing medical organizations."

Biosonics is currently marketing two patented FDA-approved electrotherapeutic medical devices: the Salitron(R), a device used in the treatment of dry mouth (1+ million sufferers), and the Cystotron(TM), a device used in the treatment of incontinence (13 million people).

Biosonics has also developed several patented medical products that incorporate the same technology as the approved products. These products cover a variety of medical conditions, such as male impotence (20 million sufferers), nasal/sinus congestion (50+ million sufferers), as well as diagnostic tools for physicians.

All statements contained in the press release are not historical facts, including but not limited to the Company's plans for product development and marketing, are based on current sales expectations. These statements are forward looking (as defined in the US Private Securities Litigation Reform Act of 1995 and the Act) in nature and involve a number of risks and uncertainties.

The factors that could cause actual results to vary materially include the availability of capital to finance operations on terms satisfactory to the company and the availability of clearances or approvals of product by federal, state and foreign government authorities.

All trademarks and registered trademarks are the property of the companies, which with they are associated.